宫癌疫苗的过去,现在和未来
Alexander C Lien1, Grace S Johnson2, Tianyun Guan3
1Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, West Des Moines, IA 50266, USA.
Vaccines
|February 26, 2025
概括
治疗性癌症疫苗在治疗宫癌方面表现有前途,即使预防性疫苗可以减少HPV感染. 需要进一步的研究来证实它们在临床环境中的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 宫癌仍然是一个重要的全球健康问题,尽管由于预防性疫苗,HPV感染率有所降低.
- 人类乳头瘤病毒 (HPV) 是宫癌的主要原因,推动了针对性治疗的研究.
- 治疗性疫苗正在成为治疗宫癌的有希望的策略.
研究的目的:
- 对治疗性宫癌疫苗的当前研究进行审查.
- 突出有前途的疫苗策略和输送方法.
- 告知妇科医生关于HPV感染管理和宫癌预防方面的进展.
主要方法:
- 关于治疗性宫癌疫苗的最新科学文献的综述.
- 对研究蛋白质,DNA和基于载体的疫苗输送系统的研究进行分析.
- 对包括免疫检查点抑制剂在内的组合疗法研究的审查.
主要成果:
- 预防性HPV疫苗已经成功降低了HPV感染和宫癌发病率.
- 各种疫苗平台 (基于蛋白质,DNA,载体) 显示出治疗应用的潜力.
- 与免疫检查点抑制剂的联合治疗可能会提高治疗效率.
结论:
- 治疗性宫癌疫苗代表了治疗的潜在进步.
- 进一步的临床研究对于验证特定疫苗策略的有效性至关重要.
- 了解HPV的作用对于开发有效的治疗干预措施至关重要.
相关概念视频
Cancer Vaccines
325
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
325
Vaccinations
43.7K
Overview
43.7K
Development of Immunocompetence
282
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
282
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K
Tumor Immunotherapy
462
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K


